Journal article
Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?
A Gafita, H Wang, A Robertson, WR Armstrong, R Zaum, M Weber, F Yagubbayli, C Kratochwil, TR Grogan, K Nguyen, F Navarro, R Esfandiari, I Rauscher, B Menze, D Elashoff, ES Delpassand, K Herrmann, J Czernin, MS Hofman, J Calais Show all
Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2022
Abstract
We aimed to systematically determine the impact of tumor burden on 68Ga-prostate-specific membrane antigen-11 (68Ga-PSMA) PET biodistribution by the use of quantitative measurements. Methods: This international multicenter, retrospective analysis included 406 men with prostate cancer who underwent 68Ga-PSMA PET/CT. Of these, 356 had positive findings and were stratified by quintiles into a very low (quintile 1, #25 cm3), low (quintile 2, 25-189 cm3), moderate (quintile 3, 189-532 cm3), high (quintile 4, 532-1,355 cm3), or very high (quintile 5, $1,355 cm3) total PSMA-positive tumor volume (PSMA-VOL). PSMA-VOL was obtained by semiautomatic segmentation of total tumor lesions using qPSMA s..
View full abstractGrants
Awarded by U.S. Department of Defense
Funding Acknowledgements
This work was partially supported by the Jonsson Comprehensive Cancer Center fellowship award. Andrei Gafita is the recipient of the Jonsson Comprehensive Cancer Center fellowship award and the Dr. Christiaan Schiepers postdoctoral fellowship award. Jeremie Calais is supported by the Prostate Cancer Foundation (2020 Young Investigator Award 20YOUN05, 2019 Challenge Award 19CHAL02) and the Society of Nuclear Medicine and Molecular Imaging (2019 Molecular Imaging Research Grant for Junior Academic Faculty) and reports prior consulting activities outside the submitted work for Advanced Accelerator Applications, Blue Earth Diagnostics, Curium Pharma, GE Healthcare, Janssen Pharmaceuticals, Progenics Pharmaceuticals, Radiomedix, and Telix Pharmaceuticals. Michael Hofman is supported by grants from the Prostate Cancer Foundation, Movember Foundation, Australian Government Medical Research Future Fund, Prostate Cancer Foundation of Australia, and U.S. Department of Defence and reports honoraria for lectures from Astellas, Janssen, Mundipharma and advisory fees from Merck/MSD. Wolfgang Fendler received financial support from the German Research Foundation (Deutsche Forschungsgemeinschaft grant FE1573/3-1/659216), Mercator Research Center Ruhr (MERCUR, An-2019-0001), IFORES (D/107-81260, D/107-30240), Doktor Robert Pfleger-Stiftung, and Wiedenfeld-Stiftung/Stiftung Krebsforschung Duisburg; was a consultant for Endocyte and BTG; and received fees from RadioMedix and Bayer outside the submitted work. Hui Wang received financial support from the China Scholarship Council. Fernando Navarro received financial support from the German Research Foundation (Deutsche Forschungsgemeinschaft research training group grant GRK 2274). Matthias Eiber reports prior consulting activities for Blue Earth Diagnostics, Progenics Pharmaceuticals, and Point Biopharma and a patent application for rhPSMA outside the submitted work. Johannes Czernin is a founder and board member of, and holds equity in, Sofie Biosciences and Trethera Therapeutics and was a consultant for Endocyte Inc. (VISION trial steering committee), Actinium Pharmaceuticals, and Point Biopharma outside the submitted work. Intellectual property is patented by the University of California and licensed to Sofie Biosciences and Trethera Therapeutics. Ken Herrmann reports personal fees from Bayer, Sofie Biosciences, SIRTEX, Adacap, Curium, Endocyte, BTG, IPSEN, Siemens Healthineers, GE Healthcare, Amgen, Novartis, ymabs, Bain Capital, and MPM Capital outside the submitted work; other fees from Sofie Biosciences; nonfinancial support from ABX; and grants from BTG. No other potential conflict of interest relevant to this article was reported.